Biennial activity report from the Korean Society of Clinical Chemistry

Organization: Korean Society of Clinical Chemistry (KSCC)

JCTLM Member status: National and Regional Member

Author(s): Jeong-Ho Kim

Author(s) email(s): jeongho@yuhs.ac; kscc1111@gmail.com

Period covered: 2018 – 2019

1. Major achievement(s) in support of standardization in laboratory medicine

(Please describe what activities your organization has undertaken related to the implementation of reference measurement systems in laboratory medicine during the last two years, including but not limited to information on: the production of certified reference materials; the development of reference measurement methods; or the establishment of calibration (reference) measurement services. Outline the measurement area(s)/measurands covered, and, provide a listing of the relevant technical/scientific publications.)

→

(1) KSCC support Korean CDC to operate National Medical Reference Laboratory for the following test item: HbA1c, Creatinine, Total cholesterol, Triglyceride, HDL cholesterol, LDL cholesterol so that they can participate RELA ring trial run by JCTLM as lab code #121. KSCC is actively cooperate with the Korean Society for Laboratory Medicine (KSLM) in terms of standardization and harmonization.

(2) KSCC started to join “The International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR)” since its inception as a council member until 2016. Although the council membership had been transferred to the KSLM from KSCC, KSCC is still actively cooperate KSLM for the harmonization activity in terms of academic activity. Dr. Eun Hee Lee, a board member of KSCC, is actively participating ICHCLR council meeting as a vice chair of the Council of the ICHCLR.

1 http://kscc.or.kr/En/About/

2 https://www.harmonization.net/
2. Planned activity(ies) in support of standardization in laboratory medicine

(Please outline R&D project(s) and/or programme(s) planned by your organization in the next two years including information on: new measurement area(s)/measurands of interest for your organization; new CRMs and renewals of materials; development of methods (new measurands and improved measurement technique/principle); and extensions of your calibration measurement service(s) portfolio.)

3. Promoting traceability in laboratory medicine

(Please describe activities your organization has undertaken during the last two years for promoting traceability in laboratory medicine including but not limited to a listing of your publication(s), presentation(s) and other communication(s) on traceability at international and national conferences or congresses, or other forums for clinical laboratory medicine)

⇒ KSCC sponsors the academic conference for the standardization and harmonization. In IFCC WorldLab Seoul 2020, we made traceability session titled “TRACEABILITY IN THE LABORATORY MEDICINE – VITAL FOR CLINICAL VALUE”. 
4. Reference laboratory networks /collaborations focusing on developing /implementing reference measurement systems
(Please describe your participation in laboratory networks, forums or professional/technical committees linked to reference measurements system development/implementation, and contributions to JCTLM Working Group activities.)
KSCC support Korean CDC to operate National Medical Reference Laboratory for the following test item: HbA1c, Creatinine, Total cholesterol, Triglyceride, HDL cholesterol, LDL cholesterol so that they can participate in the RELA ring trial run by JCTLM as lab code #121. KSCC is actively cooperating with the Korean Society for Laboratory Medicine (KSLM) in terms of standardization and harmonization.

5. Open questions and suggestions to be addressed by JCTLM

(Suggestions on issues related to standardization and metrological traceability that should be considered by the JCTLM)

Note: The information of this report will be accessible publicly on the relevant JCTLM Members webpage, unless the author of the report states otherwise. In the case the organization does not authorize the publication of the report in part or full, the author will add a statement to clarify which part(s) of the report will/will not be rendered public.